Diabetes mellitus und Herz

Katharina Schütt; Thomas Forst; Andreas L. Birkenfeld; Andreas Zirlik; Dirk Müller-Wieland; Nikolaus Marx

doi:10.1055/a-1515-9121

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2021; 16(S 02): S319-S323
DOI: 10.1055/a-1515-9121

DDG-Praxisempfehlung

Diabetes mellitus und Herz

Katharina Schütt

¹Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

,

Thomas Forst

²CRS Clinical Research Services Mannheim GmbH, Mannheim

,

Andreas L. Birkenfeld

³Medizinische Klinik IV, Universitätsklinikum Tübingen

⁴Institut für Diabetesforschung und Metabolische Erkrankungen (IDM) des Helmholtz Zentrums München an der Universität Tübingen, Deutsches Zentrum für Diabetesforschung (DZD e. V.)

,

Andreas Zirlik

⁵Klinik für Innere Medizin – Abteilung für Kardiologie, LKH-Universitätsklinikum Graz, Medizinische Universität Graz

,

Dirk Müller-Wieland

¹Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

,

Nikolaus Marx

¹Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

Literatur
1 Di Angelantonio E, Kaptoge S. Emerging Risk Factors C. et al Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52-60
2 Consentino FF, Grant PJ, Aboyans V. et al 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019;
3 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine 2015; 373
4 Neal B, Perkovic V, Mahaffey KW. et al Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;
5 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018; 380: 347-357
6 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
7 Marso SP, Bain SC, Consoli A. et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
8 Hernandez AF, Green JB, Janmohamed S. et al Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529
9 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
10 Husain M, Birkenfeld AL, Donsmark M. et al Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019; 381: 841-851
11 Marso SP, Bain SC, Consoli A. et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;
12 Nichols GA, Gullion CM, Koro CE. et al The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
13 MacDonald MR, Petrie MC, Varyani F. et al Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
14 Ponikowski P, Voors AA, Anker SD. et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
15 McMurray JJV, Solomon SD, Inzucchi SE. et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
16 Kirchhof P, Benussi S, Kotecha D. et al 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 2016;
17 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424